Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Cash from Operations of 50218000.0 for Q1 2026, down 70.71% sequentially from 29417000.0 in Q4 2025, and down 51.5% YoY from 103544168.08 in Q1 2025.
Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 50218000.0 in Q1 2026.
- Quarterly Cash from Operations fell 51.5% year-over-year to 50218000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 126513000.0 (down 124.02% YoY) and the FY2025 annual result came in at 109442000.0, down 594.56% from the prior year.
- Cash from Operations retreated to 50218000.0 in Q1 2026 per VNDA's latest filing, from 29417000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 31803000.0 in Q1 2023 and troughed at 50218000.0 in Q1 2026.
- A 5-year average of 7684235.29 and a median of 3732000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 686.04% in 2023, then tumbled 1518.99% in 2025.
- Over 5 years, Cash from Operations stood at 9416000.0 in 2022, then slumped by 139.63% to 3732000.0 in 2023, then jumped by 51.31% to 1817000.0 in 2024, then sank by 1518.99% to 29417000.0 in 2025, then plunged by 70.71% to 50218000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 50218000.0, 29417000.0, and 31626000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -31.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.07 Mn |
| Jun 30, 2026 | -31.07 Mn |
| Mar 31, 2026 | -50.22 Mn |
| Mar 31, 2026 | -50.22 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Sep 30, 2025 | -31.63 Mn |
| Sep 30, 2025 | -31.63 Mn |
| Jun 30, 2025 | -15.25 Mn |
| Jun 30, 2025 | -15.25 Mn |
| Mar 31, 2025 | -33.15 Mn |
| Mar 31, 2025 | -33.15 Mn |
| Dec 31, 2024 | -1.82 Mn |
| Dec 31, 2024 | -1.82 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Jun 30, 2024 | -6.93 Mn |
| Jun 30, 2024 | -6.93 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Mar 31, 2024 | 7.57 Mn |